FUNDAMENTALS · Fundamentals · JP Healthcare

3-D Matrix (7777) Fundamentals 2026 — P/E 9.8x, Revenue Analysis | SniperIQ

3-D Matrix (7777) is a JP-listed Healthcare company in Medical - Devices with a market capitalization of ¥41.1B, trading at ¥342.00 on the JPX. This SniperIQ fundamentals page covers 3-D Matrix's valuation (P/E 9.8x, P/B 6.2x), profitability (net margin 38.2%), revenue (¥10.9B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥41.1B
P/E (TTM)9.8x
Net Margin38.2%
Revenue (FY26)¥10.9B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is 3-D Matrix's market cap?

3-D Matrix (7777) has a market capitalization of approximately ¥41.1B, trading at ¥342.00 on the JPX. Market cap moves with the live share price.

What is 3-D Matrix's P/E ratio?

3-D Matrix's trailing twelve-month P/E ratio is 9.8x, with a price-to-book (P/B) of 6.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is 3-D Matrix?

3-D Matrix runs a net profit margin of 38.2%, a gross margin of 78.7%, and an operating margin of 12.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does 3-D Matrix generate?

3-D Matrix reported revenue of ¥10.9B for fiscal year 2026, with net income of ¥4.2B and earnings per share (EPS) of 34.89. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does 3-D Matrix pay a dividend?

3-D Matrix does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is 3-D Matrix financially healthy?

3-D Matrix carries a debt-to-equity ratio of 0.09x and a current ratio of 3.11x, with a market beta of 0.99. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is 3-D Matrix a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For 3-D Matrix (7777) the key facts are: market cap ¥41.1B, P/E 9.8x, revenue ¥10.9B, 52-week range 195-793. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track 3-D Matrix's full fundamentals live

Get 3-D Matrix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: China Resources Sanjiu Medical & Pharmaceutical (000999) fundamentals · MYUNGMOON Pharm (017180) fundamentals · Novartis India (NOVARTIND) fundamentals · Medikit (7749) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons